News and Press Releases
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2025
Ryvu Therapeutics Presents RVU305 (PRMT5i) and ONCO Prime Platform Data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates strong and selective antitumor efficacy in MTAP-deleted glioblastoma models, with confirmed brain exposure and a favorable safety profile supporting IND/CTA-enabling studies...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025
Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI design and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025
EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology
4 August 2025 -- Illinois, US -- EVERSANA, a leading provider of commercialization services to the global life sciences industry, today launched a groundbreaking pharmaceutical marketing AI agency running on...
Category: Other, Pharmaceutical
Posted: August 4, 2025
TriloDocs Ltd Joins Genactis Group
16 March 2025 -- London, UK -- We're excited to share some important news! TriloDocs has recently been acquired by Genactis: a global leader in healthcare research and technology. This...
Category: Clinical Trials, Other, Pharmaceutical
Posted: April 16, 2025
Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection
Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025
Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology
Head of Machine Learning, Lucas Camillo, to lead team with Professor Bo Wang, University of Toronto, appointed as Senior Advisor Expansion into global AI hub to accelerate growth of IP...
Category: Biotechnology, Drug Discovery
Posted: February 18, 2025
Shift Bioscience Ltd The Gurdon Institute Tennis Court Road Cambridge CB2 1QN United Kingdom
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
Clinigen Announces Strategic Partnership with Tepsivo
Expanding Client Choice with AI-Powered Pharmacovigilance Solutions 27 January 2025 -- London, UK -- Clinigen, the global specialist pharmaceutical services company, today announced a strategic partnership with Tepsivo, a pioneering...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 27, 2025
Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring
Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use...
Category: Biotechnology, Other, Pharmaceutical
Posted: December 17, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics
Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities 29 October 2024 -- New York, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: October 29, 2024
Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities
Enhancements support ADA and NAb testing workflows, boosting lab efficiency and regulatory compliance for drug development 15 October 2024 – Maryland, US – Sapio Sciences, the science-aware™ lab informatics platform,...
Category: Biotechnology, Drug Discovery
Posted: October 17, 2024
Owkin announces partnership with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer
2 October 2024 -- Paris, France -- Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 2, 2024
